Reproducibility of the Whole-Brain N-Acetylaspartate Level across Institutions, MR Scanners, and Field Strengths

References

1. ↵
   Miller DH, Grossman RI, Reingold SC, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3–24

   Abstract/FREE Full Text
2. ↵
   Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology 2002;58:S23–31

   Abstract/FREE Full Text
3. ↵
   Barkhof F, Held U, Simon JH, et al. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology 2005;65:1447–54

   Abstract/FREE Full Text
4. ↵
   Sormani MP, Bruzzi P, Comi G, et al. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis. Mult Scler 2005;11:447–49

   Abstract/FREE Full Text
5. ↵
   Sormani MP, Bruzzi P, Comi G, et al. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 2002;58:417–21

   Abstract/FREE Full Text
6. ↵
   Filippi M, Horsfield MA, Tofts PS, et al. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995;118:1601–12

   Abstract/FREE Full Text
7. ↵
   Rovaris M, Filippi M. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. Curr Opin Neurol 1999;12:337–44

   CrossRefPubMedWeb of Science
8. ↵
   Filippi M. In-vivo tissue characterization of multiple sclerosis and other white matter diseases using magnetic resonance based techniques. J Neurol 2001;248:1019–29

   CrossRefPubMedWeb of Science
9. ↵
   Filippi M, Dousset V, McFarland HF, et al. Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group. J Magn Reson Imaging 2002;15:499–504

   CrossRefPubMedWeb of Science
10. ↵
    Sormani MP, Iannucci G, Rocca MA, et al. Reproducibility of magnetization transfer ratio histogram-derived measures of the brain in healthy volunteers. AJNR Am J Neuroradiol 2000;21:133–36

    Abstract/FREE Full Text
11. ↵
    Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989;13:23–31

    CrossRefPubMedWeb of Science
12. ↵
    Danielsen EA, Ross B. Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases. New York: Marcel Dekker, Inc;1999 .
13. ↵
    Arnold DL, de Stefano N, Matthews PM, et al. N-Acetylaspartate: usefulness as an indicator of viable neuronal tissue Ann Neurol 2001;50:823; discussion 824–25
14. ↵
    Baslow MH. Functions of N-acetyl-L-aspartate and N-acetyl-l-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. J Neurochem 2000;75:453–59

    CrossRefPubMedWeb of Science
15. ↵
    Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies Neuroscience 1991;45:37–45

    CrossRefPubMedWeb of Science
16. Moffett JR, Namboodiri MA, Cangro CB, et al. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991;2:131–34

    PubMedWeb of Science
17. ↵
    Jenkins BG, Klivenyi P, Kustermann E, et al. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington’s disease mice. J Neurochem 2000;74:2108–19

    CrossRefPubMedWeb of Science
18. ↵
    Inglese M, Ge Y, Filippi M, et al. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004;21:1825–29

    CrossRefPubMedWeb of Science
19. ↵
    Brooks WM, Friedman SD, Stidley CA. Reproducibility of 1H-MRS in vivo. Magn Reson Med 1999;41:193–97

    CrossRefPubMedWeb of Science
20. Marshall I, Wardlaw J, Cannon J, et al. Reproducibility of metabolite peak areas in 1H MRS of brain. Magn Reson Imaging 1996;14:281–92

    CrossRefPubMedWeb of Science
21. ↵
    Bokde AL, Teipel SJ, Zebuhr Y, et al. A new rapid landmark-based regional MRI segmentation method of the brain. J Neurol Sci 2002;194:35–40

    CrossRefPubMedWeb of Science
22. ↵
    De Stefano N, Narayanan S, Francis SJ, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 2002;59:1565–71

    CrossRefPubMedWeb of Science
23. ↵
    Gonen O, Viswanathan AK, Catalaa I, et al. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 1998;40:684–89

    PubMedWeb of Science
24. Gonen O, Catalaa I, Babb JS, et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000;54:15–19

    Abstract/FREE Full Text
25. ↵
    Gonen O, Grossman RI. The accuracy of whole brain N-acetylaspartate quantification. Magn Reson Imaging 2000;18:1255–58

    CrossRefPubMedWeb of Science
26. ↵
    Udupa JK, Odhner D, Samarasekera S. 3DVIEWNIX: an open, transportable, multdimensional, multimodality, multiparametric imging software system. Proc SPIE 1994;2164:58–73

    CrossRef
27. De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD Neurobiol Aging 2001;22:529–39

    CrossRefPubMedWeb of Science
28. ↵
    Smith SM, De Stefano N, Jenkinson M, et al. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25:466–75

    CrossRefPubMedWeb of Science
29. ↵
    Soher BJ, van Zijl PC, Duyn JH, et al. Quantitative proton MR spectroscopic imaging of the human brain Magn Reson Med 1996;35:356–63

    PubMedWeb of Science
30. ↵
    Filippi M, Horsfield MA, Ader HJ, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998;43:499–506

    CrossRefPubMedWeb of Science
31. ↵
    Filippi M, van Waesberghe JH, Horsfield MA, et al. Interscanner variation in brain MRI lesion load measurements in MS: implications for clinical trials. Neurology 1997;49:371–77

    Abstract/FREE Full Text
32. ↵
    Molyneux PD, Brex PA, Fogg C, et al. The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study. Mult Scler 2000;6:237–40

    Abstract/FREE Full Text
33. ↵
    Filippi M, Inglese M, Rovaris M, et al. Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study. Neurology 2000;55:940–4

    Abstract/FREE Full Text